OBJECTIVE: We investigated whether the rate of viral rebound decreases with increasing duration of viral suppression and, if so, whether rebound rates in patients previously failing antiretroviral regimens ultimately decline to levels as low as those seen in patients who have never experienced virological failure. METHODS: All patients from the UK CHIC Study (n = 21 256) who achieved a viral load (VL) of < or = 50 copies/ml while receiving HAART were followed until viral rebound (two consecutive VL > 400 copies/ml). Patients could re-enter the analysis if they experienced a subsequent VL < or = 50 copies/ml. Rebound rates were calculated according to the number of regimens previously failed and duration of viral suppression. RESULTS: Of 12 648 patients on HAART 10 237 (80.9%) achieved a VL < or = 50 copies/ml. During 26 494 person-years (PY) of follow-up, 1853 (18.1%) patients experienced at least one viral rebound 'event', with 2460 events in total [rebound rate, 9.3 (range, 8.9-9.7)/100 PY). Within the first year of viral suppression, the rate of viral rebound was 8.3 (7.5-9.1)/100 PY in patients who had not previously failed treatment, increasing to 32.7 (27.6-37.8)/100 PY in patients who had failed more than four regimens. Irrespective of previous treatment failure, rebound rates in those who remained suppressed for > 4 years were similar to those in patients who had at no time experienced treatment failure. CONCLUSION: After around 4 years of viral suppression rebound rates in individuals with multiple prior treatment failures approach those of individuals with no prior treatment failure.
OBJECTIVE: We investigated whether the rate of viral rebound decreases with increasing duration of viral suppression and, if so, whether rebound rates in patients previously failing antiretroviral regimens ultimately decline to levels as low as those seen in patients who have never experienced virological failure. METHODS: All patients from the UK CHIC Study (n = 21 256) who achieved a viral load (VL) of < or = 50 copies/ml while receiving HAART were followed until viral rebound (two consecutive VL > 400 copies/ml). Patients could re-enter the analysis if they experienced a subsequent VL < or = 50 copies/ml. Rebound rates were calculated according to the number of regimens previously failed and duration of viral suppression. RESULTS: Of 12 648 patients on HAART 10 237 (80.9%) achieved a VL < or = 50 copies/ml. During 26 494 person-years (PY) of follow-up, 1853 (18.1%) patients experienced at least one viral rebound 'event', with 2460 events in total [rebound rate, 9.3 (range, 8.9-9.7)/100 PY). Within the first year of viral suppression, the rate of viral rebound was 8.3 (7.5-9.1)/100 PY in patients who had not previously failed treatment, increasing to 32.7 (27.6-37.8)/100 PY in patients who had failed more than four regimens. Irrespective of previous treatment failure, rebound rates in those who remained suppressed for > 4 years were similar to those in patients who had at no time experienced treatment failure. CONCLUSION: After around 4 years of viral suppression rebound rates in individuals with multiple prior treatment failures approach those of individuals with no prior treatment failure.
Authors: Chun Chao; Beth Tang; Leo Hurley; Michael J Silverberg; William Towner; Melissa Preciado; Michael Horberg Journal: AIDS Res Hum Retroviruses Date: 2012-04-27 Impact factor: 2.205
Authors: Jean-Médard Kankou; Olivier Bouchaud; Nathalie Lele; Marguerite Guiguet; Bruno Spire; Maria Patrizia Carrieri; Sophie Abgrall Journal: J Immigr Minor Health Date: 2019-12
Authors: Rebecca Lodwick; Dominique Costagliola; Peter Reiss; Carlo Torti; Ramón Teira; Maria Dorrucci; Bruno Ledergerber; Amanda Mocroft; Daniel Podzamczer; Alessandro Cozzi-Lepri; Niels Obel; Bernard Masquelier; Schlomo Staszewski; Federico García; Stephane De Wit; Antonella Castagna; Andrea Antinori; Ali Judd; Jade Ghosn; Giota Touloumi; Cristina Mussini; Xavier Duval; José Ramos; Laurence Meyer; Josiane Warsawski; Claire Thorne; Joan Masip; Santiago Pérez-Hoyos; Deenan Pillay; Ard van Sighem; Sergio Lo Caputo; Huldrych Günthard; Roger Paredes; Andrea De Luca; Dimitrios Paraskevis; Céline Fabre-Colin; Jesper Kjaer; Genèvieve Chêne; Jens D Lundgren; Andrew N Phillips Journal: Arch Intern Med Date: 2010-03-08
Authors: Debra A Benator; Angelo Elmi; Manuel D Rodriguez; Howard B Gale; Virginia L Kan; Heather J Hoffman; Susan Tramazzo; Karen Hall; Angela McKnight; Leah Squires Journal: AIDS Behav Date: 2015-04
Authors: Jemma O'Connor; Colette Smith; Fiona C Lampe; Margaret A Johnson; David R Chadwick; Mark Nelson; David Dunn; Alan Winston; Frank A Post; Caroline Sabin; Andrew N Phillips Journal: Lancet HIV Date: 2017-05-04 Impact factor: 12.767
Authors: Marie Ballif; Bruno Ledergerber; Manuel Battegay; Matthias Cavassini; Enos Bernasconi; Patrick Schmid; Bernard Hirschel; Hansjakob Furrer; Martin Rickenbach; Milos Opravil; Rainer Weber Journal: PLoS One Date: 2009-12-14 Impact factor: 3.240